Device Trial Radar · NCT07113223
Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,968
Planned (sponsor's estimate)
Start
Jul 23, 2025
Primary completion
Mar 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Idoven 1903 S.L.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Hospital Universitario 12 de Octubre; Fundación para la Investigación Biomédica del Hospital Gregorio Maranon; Fundación para la Investigación e Innovación Biosanitaria de Atención Primaria de la Comunidad de Madrid (FIIBAP); Instituto de Investigación Marqués de Valdecilla; Karolinska Institutet; Region Stockholm; AstraZeneca; Servicio Madrileno De Salud (SERMAS)
- First posted
- Aug 8, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The DECISION trial aims to evaluate the efficacy of an artificial intelligence (AI)-powered system, Willem™, for improving the detection of heart failure (HF) in primary care settings by interpreting electrocardiograms (ECGs). The study seeks to answer whether AI-assisted ECG interpretation enhances diagnostic accuracy and clinical outcomes compared to standard ECG evaluation in patients with suspected HF or those at high risk. This multicenter, pragmatic, randomized clinical trial involves two groups: patients receiving AI-assisted ECG analysis and those undergoing standard ECG evaluation. The study's primary analysis will compare the diagnostic performance of AI-assisted ECG versus standard ECG using sensitivity, specificity, and predictive value metrics. Secondary analyses will evaluate healthcare resource utilization, clinical outcomes, and usability feedback from healthcare providers. Results will inform the potential integration of AI-assisted ECG in routine primary care workflows for earlier HF detection and better resource allocation.
Conditions
- Heart Failure
- Cardiovascular Risk Factors
Interventions
Willem™ platform ECG assessmentDevice
AI-assisted ECG analysis via the Willem™ platform
Primary outcomes
What the sponsor says the trial is designed to measure.
- Device performance in patients with suspected Heart FailureTime frame: After performing the transthoracic echocardiography (TTE) in Visit 3 (7 days after screening)
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Hospital General Universitario Gregorio Marañón
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Primary Care: Gerencia Asistencial Atención Primaria Madrid
Madrid, Spain · Recruiting
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.